Vol 8, Supplement 6 (December 2019): Translational Cancer Research

Editorial Commentary

Discernable differences in the genetic and molecular profile of cerebellar glioblastoma
Muhibullah S. Tora, D. Cory Adamson
High predictability for identifying Lynch syndrome via microsatellite instability testing or immunohistochemistry in all Lynch-associated tumor types
John M. Carethers
Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?
Kenichi Suda
Revisiting anti-angiogenic therapy for recurrent glioblastoma
Katherine B. Peters
Robotic surgery in early-stage endometrial cancer
Giacomo Corrado, Simone Bruni, Enrico Vizza
Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
Dana Mitchell, Mahua Dey
Pseudoprogression in low-grade glioma
Jason M. Slater, Helen A. Shih
Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
Yue Zhang, Shenhong Wu
Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
Ivo W. Tremont-Lukats, Bin S. Teh
Local therapy in patients with metastatic prostate cancer: a new standard of care?
Benjamin Harper, Zachary Klaassen, Christopher J. D. Wallis
Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
Martina Chirra, Roberto Petrioli, Giandomenico Roviello
Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
Alessandro Russo, Katherine A. Scilla, Christian Rolfo
Stepping in the right direction but still some ways to go
Alfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology
Guillermo A. Gomez, Mariana Oksdath, Michael P. Brown, Lisa M. Ebert
Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
Sara Elena Rebuzzi, Francesco Facchinetti, Marcello Tiseo
Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
Alfonso Fiorelli, Fabiana Vitiello, Floriana Morgillo, Mario Santagata, Chiara Spuntarelli, Marina Di Domenico, Mario Santini, Andrea Bianco
A mechanism for the tissue specificity in BAP1 cancer syndrome
Yuichi J. Machida
Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
Shalom Lerrer, Adam Mor
Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
Yosuke Miura, Norimitsu Kasahara, Noriaki Sunaga
Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?
Brittney Chau, Ashwin Shinde, Arya Amini
Conditional reprogramming technology: a new tool for personalized medicine in bladder cancer?
Hiroshi Miyamoto
N-Myc-mediated epigenetic reprogramming in advanced prostate cancer: personalized medicine and quality of biological samples
Saverio Bettuzzi

Letter to the Editor

“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes
Eugene J. Pietzak, Hikmat Al-Ahmadie, Aleksandra Walasek, Dean F. Bajorin, Jonathan E. Rosenberg, Bernard H. Bochner, David B. Solit, Gopa Iyer

Disclosure:

This supplement was published without any sponsorship or funding.